S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
Is Gold Really Boring? (Ad)
Ride the Waves of Wealth With This Oil Tanker 17% Yield
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
Is Gold Really Boring? (Ad)
Peloton and Lululemon, Does the Deal Make Sense?
2 Seasonal Stocks to Warm Up Your Portfolio
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
3 Drone Stocks That Can Lift Your Portfolio Higher
S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
Is Gold Really Boring? (Ad)
Ride the Waves of Wealth With This Oil Tanker 17% Yield
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
Is Gold Really Boring? (Ad)
Peloton and Lululemon, Does the Deal Make Sense?
2 Seasonal Stocks to Warm Up Your Portfolio
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
3 Drone Stocks That Can Lift Your Portfolio Higher
S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
Is Gold Really Boring? (Ad)
Ride the Waves of Wealth With This Oil Tanker 17% Yield
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
Is Gold Really Boring? (Ad)
Peloton and Lululemon, Does the Deal Make Sense?
2 Seasonal Stocks to Warm Up Your Portfolio
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
3 Drone Stocks That Can Lift Your Portfolio Higher
S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
Is Gold Really Boring? (Ad)
Ride the Waves of Wealth With This Oil Tanker 17% Yield
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
Is Gold Really Boring? (Ad)
Peloton and Lululemon, Does the Deal Make Sense?
2 Seasonal Stocks to Warm Up Your Portfolio
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
3 Drone Stocks That Can Lift Your Portfolio Higher
NASDAQ:ACAD

ACADIA Pharmaceuticals (ACAD) Price Target & Analyst Ratings

$21.47
+0.63 (+3.02%)
(As of 10/2/2023 ET)
Compare
Today's Range
$20.31
$21.52
50-Day Range
$20.84
$30.32
52-Week Range
$13.73
$33.99
Volume
2.40 million shs
Average Volume
1.59 million shs
Market Capitalization
$3.52 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.81

ACADIA Pharmaceuticals Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 13 Analyst Ratings

Consensus Analyst Price Target

$31.81
48.17% Upside
High Prediction$95.00
Average Prediction$31.81
Low Prediction$12.00
TypeCurrent
10/3/22 to 10/3/23
1 Month Ago
9/3/22 to 9/3/23
3 Months Ago
7/5/22 to 7/5/23
1 Year Ago
10/3/21 to 10/3/22
Consensus Rating
Hold
Hold
Moderate Buy
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
6 Buy rating(s)
10 Buy rating(s)
8 Buy rating(s)
Hold
6 Hold rating(s)
6 Hold rating(s)
5 Hold rating(s)
8 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$31.81$31.81$26.29$21.75
Predicted Upside48.17% Upside29.11% Upside38.48% Upside21.42% Upside
Get ACADIA Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ACAD and its competitors with MarketBeat's FREE daily newsletter.


ACAD Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ACAD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

ACADIA Pharmaceuticals Stock vs. The Competition

TypeACADIA PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.38
2.66
2.49
Consensus RatingHoldModerate BuyHold
Predicted Upside48.17% Upside842.50% Upside698.29% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/22/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$42.00+39.77%
8/7/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$28.00 ➝ $29.00+7.53%
8/3/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingEqual Weight ➝ Equal Weight$30.00+7.37%
8/3/2023Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$39.00 ➝ $38.00+36.01%
8/3/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$33.00+13.01%
8/3/2023Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMarket Perform ➝ Market Perform$25.00-14.38%
7/14/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral$21.60 ➝ $27.00-13.21%
7/14/2023Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$28.00 ➝ $33.00+12.36%
7/14/2023JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetMarket Outperform$31.00 ➝ $39.00+51.16%
6/15/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$26.00 ➝ $29.00+20.13%
4/28/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$93.00 ➝ $95.00+363.41%
4/14/2023Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingNeutral$20.00+4.44%
3/14/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$22.00 ➝ $25.00+28.80%
3/14/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$10.00 ➝ $15.00-22.72%
11/3/2022The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Sell$15.00 ➝ $12.00-19.03%
11/1/2022Loop Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold$17.00+6.05%
(Data available from 10/3/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












ACAD Price Target - Frequently Asked Questions

What is ACADIA Pharmaceuticals's consensus rating and price target?

According to the issued ratings of 13 analysts in the last year, the consensus rating for ACADIA Pharmaceuticals stock is Hold based on the current 1 sell rating, 6 hold ratings and 6 buy ratings for ACAD. The average twelve-month price prediction for ACADIA Pharmaceuticals is $31.81 with a high price target of $95.00 and a low price target of $12.00. Learn more on ACAD's analyst rating history.

Do Wall Street analysts like ACADIA Pharmaceuticals more than its competitors?

Analysts like ACADIA Pharmaceuticals less than other Medical companies. The consensus rating for ACADIA Pharmaceuticals is Hold while the average consensus rating for medical companies is Moderate Buy. Learn more on how ACAD compares to other companies.

Does ACADIA Pharmaceuticals's stock price have much upside?

According to analysts, ACADIA Pharmaceuticals's stock has a predicted upside of 29.11% based on their 12-month price targets.

What analysts cover ACADIA Pharmaceuticals?

Stock Ratings Reports and Tools

This page (NASDAQ:ACAD) was last updated on 10/3/2023 by MarketBeat.com Staff

My Account -